CL2015001241A1 - Uso de interleucina 2 (il-2) para tratar trastornos inflamatorios o relacionados con la autoinmunidad (div. sol. n° 2608-13) - Google Patents
Uso de interleucina 2 (il-2) para tratar trastornos inflamatorios o relacionados con la autoinmunidad (div. sol. n° 2608-13)Info
- Publication number
- CL2015001241A1 CL2015001241A1 CL2015001241A CL2015001241A CL2015001241A1 CL 2015001241 A1 CL2015001241 A1 CL 2015001241A1 CL 2015001241 A CL2015001241 A CL 2015001241A CL 2015001241 A CL2015001241 A CL 2015001241A CL 2015001241 A1 CL2015001241 A1 CL 2015001241A1
- Authority
- CL
- Chile
- Prior art keywords
- autoimmune
- div
- interleukin
- sol
- related disorders
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Virology (AREA)
- Psychiatry (AREA)
- Gynecology & Obstetrics (AREA)
- Hospice & Palliative Care (AREA)
- Molecular Biology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Ophthalmology & Optometry (AREA)
- Vascular Medicine (AREA)
Abstract
La presente invención se refiere tratamientos novedosos basados en IL-2 para tratar enfermedades autoinmunes e inflamatorias. De forma más específica, la presente invención se refiere al uso de una dosis baja de IL-2 para el tratamiento de la diabetes de tipo I y otras enfermedades autoinmunes y/o inflamatorias.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161451663P | 2011-03-11 | 2011-03-11 | |
EP11305269 | 2011-03-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2015001241A1 true CL2015001241A1 (es) | 2015-08-14 |
Family
ID=57232567
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2013002608A CL2013002608A1 (es) | 2011-03-11 | 2013-09-10 | Uso de dosis bajas de il -2 para tratar transtornos inflamatorios y relacionados con la autoinmunidad |
CL2015001241A CL2015001241A1 (es) | 2011-03-11 | 2015-05-08 | Uso de interleucina 2 (il-2) para tratar trastornos inflamatorios o relacionados con la autoinmunidad (div. sol. n° 2608-13) |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2013002608A CL2013002608A1 (es) | 2011-03-11 | 2013-09-10 | Uso de dosis bajas de il -2 para tratar transtornos inflamatorios y relacionados con la autoinmunidad |
Country Status (5)
Country | Link |
---|---|
US (4) | US9669071B2 (es) |
JP (3) | JP6416855B2 (es) |
BR (1) | BR112013023151A2 (es) |
CL (2) | CL2013002608A1 (es) |
ES (1) | ES2811624T3 (es) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112013023151A2 (pt) | 2011-03-11 | 2020-09-15 | Assistance Publique - Hôpitaux De Paris | interleucina-2 para uso no tratamento de desordem auto-imune, !muno-relacionada ou inflamatória e método para determinar se um regime ou dose de il-2 tem de ser modificado |
WO2012164083A1 (en) | 2011-06-01 | 2012-12-06 | Actogenix N.V. | Polycistronic expression system for bacteria |
JP6612258B2 (ja) | 2014-04-22 | 2019-11-27 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | 自己免疫疾患の診断のための方法 |
SI3180020T1 (sl) | 2014-08-11 | 2019-04-30 | Delinia, Inc. | Modificirane variante IL-2, ki selektivno aktivirajo regulatorne celice T, za zdravljenje avtoimunih bolezni |
GB201515244D0 (en) * | 2015-08-27 | 2015-10-14 | Univ Birmingham | Treatment of inflammatory disease or condition |
DK3402499T3 (da) * | 2016-01-14 | 2021-09-27 | Intrexon Actobiotics Nv | Sammensætninger og fremgangsmåder til behandlingen af type 1 diabetes |
US20170204154A1 (en) | 2016-01-20 | 2017-07-20 | Delinia, Inc. | Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases |
SG11201903882VA (en) | 2016-11-08 | 2019-05-30 | Delinia Inc | Il-2 variants for the treatment of autoimmune diseases |
EP3596108A4 (en) | 2017-03-15 | 2020-12-23 | Pandion Operations, Inc. | TARGETED IMMUNOTOLERANCE |
JP2020521452A (ja) | 2017-05-24 | 2020-07-27 | パンディオン・セラピューティクス・インコーポレイテッド | 標的化免疫寛容 |
US10174091B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
MX2021010017A (es) | 2019-02-20 | 2021-11-17 | Ksl Biomedical Inc | Metodo para predecir y monitorear la eficacia de la terapia con il-2 e hidroxicloroquina en dosis bajas en enfermedades autoinmunes y su uso a largo plazo en afecciones relacionadas con la autoinmunidad. |
CN109999179A (zh) * | 2019-05-08 | 2019-07-12 | 山东省分析测试中心 | 低剂量白介素2用于制备治疗阿尔茨海默病药物中的应用 |
JP2022533702A (ja) | 2019-05-20 | 2022-07-25 | パンディオン・オペレーションズ・インコーポレイテッド | MAdCAM標的化免疫寛容 |
US20210059962A1 (en) * | 2019-09-03 | 2021-03-04 | Regen BioPharma, Inc. | Stimulation of t regulatory cells by cannabidiol as a means of treating arthritis and autoimmunity |
US20230256015A1 (en) * | 2019-12-18 | 2023-08-17 | Washington University | Compositions and methods for treatment of headache disorders and neuropathic pain |
CA3166509A1 (en) | 2020-01-14 | 2021-07-22 | Synthekine, Inc. | Biased il2 muteins methods and compositions |
US11981715B2 (en) | 2020-02-21 | 2024-05-14 | Pandion Operations, Inc. | Tissue targeted immunotolerance with a CD39 effector |
US20230272094A1 (en) | 2020-08-05 | 2023-08-31 | Synthekine, Inc. | Il2rb/il2rg synthetic cytokines |
CA3204162A1 (en) | 2021-01-11 | 2022-07-14 | Robert Kastelein | Compositions and methods related to receptor pairing |
WO2024043975A1 (en) * | 2022-08-25 | 2024-02-29 | Board Of Regents Of The University Of Nebraska | Induction and expansion of regulatory t cells |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0262802A3 (en) | 1986-09-01 | 1990-01-31 | Takeda Chemical Industries, Ltd. | Medicament for the treatment or improvement of rheumatoid arthritis or systemic lupus erythematosus |
JPS63183538A (ja) * | 1986-09-01 | 1988-07-28 | Takeda Chem Ind Ltd | 関節リウマチまたは全身性エリテマト−デスの改善,治療剤 |
US5466447A (en) | 1988-06-29 | 1995-11-14 | Amgen Inc. | Method for treating psoriasis |
AU7578091A (en) | 1990-03-19 | 1991-10-21 | Brigham And Women's Hospital | Treatment of cachexia with interleukin 2 |
US5466477A (en) | 1993-11-08 | 1995-11-14 | Hawkins Chemical, Inc. | Preparation of process cheese using liquid sodium phosphate |
FR2769505B1 (fr) | 1997-10-10 | 2000-06-30 | Michael Gerard Tovey | Compositions de cytokines a administrer a la muqueuse buccale, et leurs utilisations |
GB9724838D0 (en) | 1997-11-26 | 1998-01-21 | Franks Christopher R | Compositions |
WO2002078624A2 (en) | 2001-03-30 | 2002-10-10 | Mayo Foundation For Medical Education And Research | Aerosol administration of interleukin-2 liposomes |
EP1426052B1 (en) * | 2002-12-02 | 2009-09-02 | Innate Pharma | Compositions comprising interleukin-2 and gamma-delta T cell activator and uses thereof |
US7569215B2 (en) | 2003-07-18 | 2009-08-04 | Massachusetts Institute Of Technology | Mutant interleukin-2 (IL-2) polypeptides |
US20070098685A1 (en) | 2005-01-19 | 2007-05-03 | Brand Stephen J | Methods and kits to treat chronic inflammatory immune diseases by administering a proteasome inhibitor and an interleukin 2 receptor agonist |
MX2007009012A (es) * | 2005-01-27 | 2007-09-14 | Novartis Vaccines & Diagnostic | Metodos para tratar carcinoma de celulas renales. |
ES2610327T3 (es) | 2008-03-13 | 2017-04-27 | Biotest Ag | Régimen de dosificación de anticuerpos anti-CD4 para el tratamiento de enfermedades autoinmunitarias |
DE102008023820A1 (de) | 2008-05-08 | 2009-11-12 | Aicuris Gmbh & Co. Kg | Mittel zur Behandlung und/oder Prophylaxe einer Autoimmunerkrankung und zur Bildung von Regulatorischen T-Zellen |
WO2010049438A2 (en) | 2008-10-30 | 2010-05-06 | Innate Pharma | Improved methods of using phosphoantigens for the treatment of diseases |
ES2825173T3 (es) | 2009-01-21 | 2021-05-14 | Amgen Inc | Composiciones y métodos de tratamiento de enfermedades inflamatorias y autoinmunitarias |
CN102462837B (zh) | 2010-11-19 | 2016-08-03 | 生物林格斯Ip有限公司 | 抗炎组合物 |
BR112013023151A2 (pt) | 2011-03-11 | 2020-09-15 | Assistance Publique - Hôpitaux De Paris | interleucina-2 para uso no tratamento de desordem auto-imune, !muno-relacionada ou inflamatória e método para determinar se um regime ou dose de il-2 tem de ser modificado |
-
2012
- 2012-03-09 BR BR112013023151-3A patent/BR112013023151A2/pt not_active Application Discontinuation
- 2012-03-09 ES ES18179669T patent/ES2811624T3/es active Active
- 2012-03-09 US US14/004,211 patent/US9669071B2/en active Active
-
2013
- 2013-09-10 CL CL2013002608A patent/CL2013002608A1/es unknown
-
2015
- 2015-05-08 CL CL2015001241A patent/CL2015001241A1/es unknown
-
2016
- 2016-12-01 JP JP2016234087A patent/JP6416855B2/ja active Active
-
2017
- 2017-05-05 US US15/588,226 patent/US10293028B2/en active Active
-
2018
- 2018-10-04 JP JP2018189159A patent/JP2019014743A/ja active Pending
-
2019
- 2019-03-22 US US16/361,902 patent/US10765723B2/en active Active
-
2020
- 2020-07-10 US US16/925,983 patent/US11559566B2/en active Active
- 2020-10-22 JP JP2020177184A patent/JP2021006591A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
US10293028B2 (en) | 2019-05-21 |
US20210038691A1 (en) | 2021-02-11 |
BR112013023151A2 (pt) | 2020-09-15 |
JP6416855B2 (ja) | 2018-10-31 |
US20140004080A1 (en) | 2014-01-02 |
JP2021006591A (ja) | 2021-01-21 |
US11559566B2 (en) | 2023-01-24 |
ES2811624T3 (es) | 2021-03-12 |
CL2013002608A1 (es) | 2014-05-30 |
JP2017061551A (ja) | 2017-03-30 |
US20190351023A1 (en) | 2019-11-21 |
US20170304402A1 (en) | 2017-10-26 |
US9669071B2 (en) | 2017-06-06 |
JP2019014743A (ja) | 2019-01-31 |
US10765723B2 (en) | 2020-09-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2015001241A1 (es) | Uso de interleucina 2 (il-2) para tratar trastornos inflamatorios o relacionados con la autoinmunidad (div. sol. n° 2608-13) | |
CY1121203T1 (el) | Θεραπευτικες χρησεις της εμπαγλιφλοζινης | |
MX2013010342A (es) | Uso de dosis bajas de il-2 para tratar transtornos inflamatorios o relacionados con la autoinmunidad. | |
EA201490748A1 (ru) | Лечение рассеянного склероза комбинацией лахинимода и финголимода | |
UY34859A (es) | Análogos peptídicos de la exendina 4. | |
BR112013029256A2 (pt) | "combinações farmacêuticas para uso no tratamento de pacientes com diabetes tipo 2, método de tratamento, e usos de lixisenatida e metformina". | |
BR112015027282A2 (pt) | fenfluramina para uso no tratamento de síndrome de dravet | |
GT201400089A (es) | Nuevos compuestos inhibidores de la fosfodiesterasa del tipo 10a | |
GT201300215A (es) | Inhibidores de glucosilceramida sintasa | |
EA201290964A1 (ru) | Пептидные конъюгаты агонистов рецептора glp-1 и их применение | |
BR112013028666A2 (pt) | compostos de pirazolo sulfonamida tricícilos e métodos para fazer e usar o mesmo | |
CR20130377A (es) | Métodos y productos de fármaco para tratar enfermedad de alzheimer | |
UA118558C2 (uk) | Пептидна сполука | |
AR101740A1 (es) | Terapia de combinación y composiciones | |
EA201590654A1 (ru) | Комбинация разагилина и придопидина для лечения нейродегенеративных нарушений, в частности болезни хантингтона | |
UA113849C2 (xx) | Застосування сигма-лігандів при болю, пов'язаному з діабетом 2 типу | |
AU2014265671A8 (en) | Substituted bridged urea analogs as sirtuin modulators | |
GT201500168A (es) | Polipéptidos estabilizados del factor de crecimiento tipo insulina | |
CO6592101A2 (es) | Metodos para tratar ulceras de pie de diabetico | |
MX2013011124A (es) | Compuestos para el tratamiento del sindrome metabolico. | |
CL2016001578A1 (es) | Piperidiniltetrahidroquinolinas sustituidas y su uso como antagonistas de los adenoreceptores alpha-2c. | |
DOP2017000123A (es) | Análogos de urea unidos sustituidos como moduladores de sirtuina | |
EA201690191A1 (ru) | Фармацевтическая композиция для замедленного высвобождения ланреотида | |
UY35328A (es) | Tratamiento de formas progresivas de esclerosis múltiple con laquinimod | |
BR112015010223A2 (pt) | compostos tricíclicos para o uso no tratamento e/ou controle de obesidade |